SEC Filing Summary for Centessa Pharmaceuticals plc

On June 24, 2026, Centessa Pharmaceuticals plc completed a scheme of arrangement whereby Eli Lilly and Company acquired all outstanding ordinary shares. Shareholders received $38.00 in cash per ordinary share, along with a contingent value right (CVR) potentially worth up to an additional $9.00 per share, contingent on specified milestones. This transaction, detailed in the Transaction Agreement dated March 31, 2026, resulted in the automatic transfer of shares. Reporting owners, including INDEX VENTURES LIFE VI (JERSEY) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd, who previously held significant stakes, are noted as having disposed of their holdings. Their ownership nature is detailed with disclaimers regarding Section 16 beneficial ownership. The filing indicates that the transactions were not subject to Section 16 reporting requirements.